Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer |
| |
| Authors: | Jong Gwang Kim Sang Kyun Sohn Hong Suk Song Ki-Young Kwon Young Rok Do Kyung Hee Lee Myung Soo Hyun Hun Mo Ryoo Sung Hwa Bae Keon Uk Park Jin Ho Baek Won Sik Lee Joo Seop Chung Goon Jae Cho Chang-Hak Sohn Jung Soon Jang Ho Young Chung Wansik Yu |
| |
| Affiliation: | (1) Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea;(2) Department of Oncology/Hematology, Dongsan Medical Center, Keimyung University School of Medicine, 194 Dongsan-dong, Jung-ku, Daegu, 700-712, Korea;(3) Department of Oncology/Hematology, Yeungnam University Hospital, Daegu, Korea;(4) Department of Oncology/Hematology, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea;(5) Department of Oncology/Hematology, Dongguk University Medical Center, Dongguk University College of Medicine, Gyeongju, Korea;(6) Department of Oncology/Hematology, Daegu Fatima Hospital, Daegu, Korea;(7) Department of Oncology/Hematology, Pusan National University Hospital, Busan, Korea;(8) Department of Oncology/Hematology, Inje University Hospital, Busan, Korea;(9) Department of Oncology/Hematology, Gyeongsang National University Hospital, Jinju, Korea;(10) Department of General Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea |
| |
| Abstract: | Purpose Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer. Patients and methods Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m2 plus cisplatin 35 mg/m2 on days 1 and 8 based on a 3-week cycle. Results Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no treatment-related deaths. Conclusion A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer. |
| |
| Keywords: | Paclitaxel Cisplatin Chemotherapy Gastric cancer |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
